Science Explorer Back to mapMap

Most cited papers from Endo Pharmaceuticals (United States)

What are the most cited papers from Endo Pharmaceuticals (United States)?

The most cited paper from Endo Pharmaceuticals (United States) is "Core outcome measures for chronic pain clinical trials: IMMPACT recommendations" (Robert H. Dworkin et al., 2004), with 3,789 citations. Next come "Core outcome domains for chronic pain clinical trials: IMMPACT recommendations" (3,518) and "Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations" (3,496).

Showing 50 of 62 papers. Every paper with more than 75 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Core outcome measures for chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin et al. · Pain 6 Nov 2004 3,789
2 Core outcome domains for chronic pain clinical trials: IMMPACT recommendations Dennis C. Turk et al. · Pain 22 Sep 2003 3,518
3 Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations Robert H. Dworkin et al. · Journal of Pain Open access 13 Dec 2007 3,496
4 Perspectives on cancer therapy-induced mucosal injury Stephen T. Sonis, Linda S. Elting, Dorothy M. K. Keefe et al. · Cancer Open access 2004 1,420
5 Core Outcome Domains and Measures for Pediatric Acute and Chronic/Recurrent Pain Clinical Trials: PedIMMPACT Recommendations Patrick J. McGrath et al. · Journal of Pain Open access 18 Jun 2008 862
6 Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis Edward B. Rubenstein, Douglas E. Peterson, Mark Schubert et al. · Cancer 2004 828
7 The burdens of cancer therapy Linda S. Elting, Catherine D. Cooksley, Mark Steven Chambers et al. · Cancer Open access 14 Aug 2003 621
8 Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy Yadollah Harati, Clifton L. Gooch, Michael Swenson et al. · Neurology Jun 1998 544
9 Migraine prevalence by age and sex in the United States: A life-span study TW Victor, Xiaojun Hu, JC Campbell et al. · Cephalalgia Open access 12 Mar 2010 517
10 SPSS-X Advanced Statistics Guide Mark Von Tress · Technometrics May 1988 496
11 Patient-Controlled Analgesia Jeffrey A. Grass · Anesthesia & Analgesia 12 Oct 2005 451
12 Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin et al. · Pain 9 Mar 2010 386
13 Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data R. Puenpatom, Timothy W. Victor · Postgraduate Medicine Nov 2009 358
14 PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial Sheena McCormack et al. · The Lancet Open access 21 Sep 2010 336
15 Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? Stephen P. Bruehl, Norman R. Harden, Bradley S. Galer et al. · Pain 2002 309
16 Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations Dennis C. Turk et al. · Pain 26 Oct 2006 305
17 Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin et al. · Pain 9 Apr 2012 293
18 Case fatality and population mortality associated with anaphylaxis in the United States Larry Ma, Theodore M. Danoff, Larry Borish · Journal of Allergy and Clinical Immunology Open access 14 Dec 2013 246
19 The Role of Intrathecal Drugs in the Treatment of Acute Pain James P. Rathmell, Timothy R. Lair, Bushra Nauman · Anesthesia & Analgesia 12 Oct 2005 245
20 Clinical Application of Opioid Equianalgesic Data Arnold R. Gammaitoni, Perry G. Fine, Nancy A. Álvarez et al. · Clinical Journal of Pain 27 Aug 2003 244
21 The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale Bradley S. Galer, Mark P. Jensen, Tina Ma et al. · Clinical Journal of Pain Sep 2002 243
22 Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women Salim S. Abdool Karim, Barbra A. Richardson, Gita Ramjee et al. · AIDS Open access 16 Feb 2011 234
23 Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations Dennis C. Turk et al. · Pain 16 Aug 2008 219
24 Safety and Tolerability of the Lidocaine Patch 5%, a Targeted Peripheral Analgesic: A Review of the Literature Arnold R. Gammaitoni, Nancy A. Álvarez, Bradley S. Galer · The Journal of Clinical Pharmacology Feb 2003 203
25 Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial Karim S. Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology Open access 25 Jun 2014 196
26 Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms. Masahiro Endo, I Kanda, S Hosoda et al. · Circulation Open access Jul 1975 189
27 Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia Pamela Stitzlein Davies, Bradley S. Galer · Drugs 2004 181
28 Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study Martin E Hale, Harry B Ahdieh, Tina Ma et al. · Journal of Pain Open access 5 Dec 2006 170
29 The Pain Quality Assessment Scale: Assessment of Pain Quality in Carpal Tunnel Syndrome Mark P. Jensen, Arnold R. Gammaitoni, David Olufemi Olaleye et al. · Journal of Pain Open access Nov 2006 162
30 Melanoma, Version 2.2013 Daniel G. Coit et al. · Journal of the National Comprehensive Cancer Network Apr 2013 155
31 Fatigue properties of AlSi10Mg produced by Additive Layer Manufacturing Julius N. Domfang Ngnekou, Yves Nadot, Gilbert Hénaff et al. · International Journal of Fatigue Open access 4 Oct 2018 147
32 Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations Nathaniel P. Katz, Edgar H. Adams, Howard D. Chilcoat et al. · Clinical Journal of Pain Oct 2007 146
33 Research design considerations for chronic pain prevention clinical trials Jennifer S. Gewandter et al. · Pain Open access 16 Apr 2015 145
34 Symptom Profiles Differ in Patients With Neuropathic Versus Non-neuropathic Pain Robert H. Dworkin, Mark P. Jensen, Arnold R. Gammaitoni et al. · Journal of Pain Open access 2 Sep 2006 139
35 A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain Nathaniel P. Katz, Richard L Rauck, Harry B Ahdieh et al. · Current Medical Research and Opinion 11 Dec 2006 136
36 Respiratory Depression After Neuraxial Opioids in the Obstetric Setting Brendan Carvalho · Anesthesia & Analgesia 13 Aug 2008 135
37 OKT3 MONOCLONAL ANTIBODY PLASMA LEVELS DURING THERAPY AND THE SUBSEQUENT DEVELOPMENT OF HOST ANTIBODIES TO OKT3 Gideon Goldstein, Anthony J. Fuccello, Douglas J. Norman et al. · Transplantation Nov 1986 123
38 Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial Alan K. Matsumoto, Najib Babul, Harry B Ahdieh · Pain Medicine Sep 2005 118
39 Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale Charles E. Argoff, Bradley S. Galer, Mark P. Jensen et al. · Current Medical Research and Opinion Nov 2004 117
40 A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systems MJ Millan, Andrzej Członkowski, CW Pilcher et al. · Journal of Neuroscience Open access 1987 117
41 Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs Huaihung Danny Kao, Ashraf Traboulsi, Soichi Itoh et al. · Pharmaceutical Research Aug 2000 117
42 Pharmacokinetics and Tolerability of Lidocaine Patch 5% with Extended Dosing Arnold R. Gammaitoni, Matthew W. Davis · Annals of Pharmacotherapy Feb 2002 111
43 Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations Jennifer S. Gewandter et al. · Pain Open access 24 May 2014 111
44 Prostate Cancer Early Detection, Version 1.2014 Peter R. Carroll et al. · Journal of the National Comprehensive Cancer Network Open access Sep 2014 107
45 Central Nervous System Cancers, Version 2.2014 Burt Nabors et al. · Journal of the National Comprehensive Cancer Network Open access 31 Oct 2014 105
46 MorphiDex® (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance Bradley S. Galer, David J. Lee, Tina Ma et al. · Pain 21 Apr 2005 103
47 Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale Mark P. Jensen, Robert H. Dworkin, Arnold R. Gammaitoni et al. · Journal of Pain Open access Feb 2005 101
48 Ventricular Irritability Associated with the Use of Naloxone Hydrochloride: Two Case Reports and Laboratory Assessment of the Effect of the Drug on Cardiac Excitability Lawrence L. Michaelis, Paul R. Hickey, Thomas Arkle Clark et al. · The Annals of Thoracic Surgery Dec 1974 100
49 Pharmacokinetics and safety of continuously applied lidocaine patches 5% Arnold R. Gammaitoni, Nancy A. Álvarez, Bradley S. Galer · American Journal of Health-System Pharmacy 15 Nov 2002 99
50 Lidocaine Patch 5% Reduces Pain Intensity and Interference with Quality of Life in Patients With Postherpetic Neuralgia: An Effectiveness Trial Nathaniel P. Katz, Arnold R. Gammaitoni, Matthew W. Davis et al. · Pain Medicine Dec 2002 98

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.